Biotech

All Articles

AN 2 halves headcount, quits stage 3 test after records let down

.AN2 Rehabs is actually reviewing its organization in reaction to lackluster midphase data, swearing...

Merck pays $700M for bispecific, snooping autoimmune opening as well as chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying out $700 million in advance to test Amgen in a blood cancer marke...

Gilead spends J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences on the verge of an FDA decision for its liver ailment medication seladelpar, t...

' All hands on deck' at Lilly as peers target weight problems market

.CEO David Ricks can easily find the business setting up tents at basecamp responsible for Eli Lilly...

Entero laying off personnel, leaving workplace and also stopping briefly R&ampD

.Mattress Liquidators has switched Entero Therapies white as a slab. The lender purchased Entero to ...

Exelixis loses ADC after deciding it is actually no suit for Tivdak

.Exelixis is actually giving up on its own cells factor (TF)- targeting antibody-drug conjugate afte...

Relay dislikes SHP2 inhibitor after Genentech leaves behind

.Three weeks after Roche's Genentech device walked away from an SHP2 prevention deal, Relay Rehab ha...

Stoke's Dravet syndrome med discharged of predisposed clinical grip

.Stoke Therapeutics' Dravet syndrome medicine has been actually devoid of a predisposed grip, cleari...

Fierce Biotech's Gabrielle Masson provides Intense 15 at NYSE

.Tough Biotech Colleague Publisher Gabrielle Masson showed the 2024 course of Tough 15 champions on ...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has axed its own once-monthly dual GLP-1/ GIP receptor agonist, finishing (PDF) develo...